Study on Transdermal Estradiol and Oral Progesterone for Depression Prevention During Menopause
Introduction
A recent study examined the effectiveness of transdermal estradiol combined with oral progesterone in preventing depression during menopause. The period of menopausal transition and early postmenopause is often linked to significant increases in depressive symptoms and major depressive disorder. Women with a history of depression, abuse, or recent stressful life events may face a heightened risk for these symptoms. Additionally, severe vasomotor symptoms such as hot flashes and night sweats have been identified as factors that may contribute to depression in this demographic.
Research Background
The fluctuations of estradiol, a key form of estrogen, have been associated with depressive symptoms. While estrogen therapy, with or without progesterone, has shown effectiveness in treating depressive symptoms in perimenopausal women, its potential for prevention during the menopausal transition and early postmenopause has not been thoroughly investigated. To address this knowledge gap, researchers from North America conducted a double-blind, placebo-controlled randomized trial at the University of North Carolina at Chapel Hill from October 2010 to February 2016. The findings were published in JAMA Psychiatry.
Study Design
The study aimed to assess the efficacy of an estradiol patch combined with intermittent micronized progesterone (TE+IMP) in preventing depressive symptoms in non-depressed women with a stable mood during perimenopause or early postmenopause. The researchers also sought to identify which groups of women were more susceptible to depressive symptoms, focusing on those with severe vasomotor symptoms, a history of depression, or those who had recently experienced stressful life events. Baseline estradiol levels and reproductive stage at enrollment were also evaluated.
Participants were recruited via community advertisements and social media, receiving monetary compensation for their involvement. A total of 172 women aged 45 to 60 participated in the study. Participants were randomly assigned to receive either TE+IMP or a placebo. The estradiol patches delivered 0.1 mg over 12 months, while progesterone was administered every two to three months for 12 days at a daily dose of 200 mg. The effects of estradiol alone were measured during seven clinic visits when participants were not on progesterone. Depressive symptoms were assessed using the Center for Epidemiologic Studies–Depression Scale (CES-D), with a score of 16 or higher indicating clinically elevated depressive symptoms.
Results
Sixty-six percent of participants completed all seven clinic visits, while 85% attended at least four. Results indicated that women in the placebo group exhibited clinically elevated signs of depression compared to those receiving TE+IMP. The placebo group was more likely to score at or above the clinical depression threshold at least once during the study and had higher mean CES-D scores throughout the 12-month period. Notably, TE+IMP was particularly effective in preventing depressive symptoms among women in the early menopausal transition and those with a higher number of stressful life events prior to enrollment. However, baseline estradiol levels, vasomotor symptoms, and histories of depression or abuse did not significantly affect the results.
Conclusion
This study suggests that TE+IMP is a promising strategy for preventing depressive symptoms in women undergoing the menopausal transition. However, participants receiving this intervention reported heavier or prolonged bleeding compared to those in the placebo group. Clinicians are encouraged to identify and support women in the early stages of menopause and those experiencing multiple recent stressful life events, as they may benefit most from this therapy. Further research is warranted to better understand the mechanisms by which TE+IMP may influence estradiol levels and mitigate depression during various stages of the menopausal transition.
Reference
Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial. JAMA Psychiatry. Published online January 10, 2018. doi:10.1001/jamapsychiatry.2017.3998